Navigation Links
Bert W. O'Malley, M.D., Recipient of the 2008 National Medal for Science, Joins Bionovo's Scientific Advisory Board
Date:2/17/2009

EMERYVILLE, Calif., Feb. 17 /PRNewswire-FirstCall/ -- Bionovo Inc. (Nasdaq: BNVI) announced today the appointment of Bert O'Malley, M.D., to the company's Scientific Advisory Board. Dr. O'Malley, the recipient of the National Medal for Science in 2008, has extensive experience in academic research as well as with pharmaceutical and biotech companies.

"We are very excited to have Dr. O'Malley on the scientific advisory board as we are advancing our novel hormonal drug candidates," said Isaac Cohen, O.M.D., Bionovo's Chairman and CEO. He added, "Dr. O'Malley, a member of the National Academy of Sciences, and the recipient of the 2008 National Medal for Science, is a pioneer in biomedical research. Dr. O'Malley's landmark discoveries revealed the mechanism of hormone action and the critical importance of a previously undiscovered superfamily of mediators, the nuclear receptor coregulators. No doubt these discoveries have transformed the future of health and our ability to select safer, more targeted therapies for many critical indications. We are looking forward to collaborating with him on current and future indications involving nuclear receptors."

Dr. O'Malley states, "I'm delightfully surprised and impressed by the selectivity, safety and clinical effects of Menerba, Bionovo's drug candidate for menopausal hot flashes. To date, it is perhaps the most impressive SERM I've encountered. The utilization of natural compounds with historical clinical utility, and the targeted mechanism of action seems to result in a safer drug with exciting clinical results. I believe this strategy is propitious and will provide new therapies for many indications that currently have unmet or poorly met medical needs. I hope our collaboration will further expand therapeutic choices for a number of significant diseases with unmet need
'/>"/>

SOURCE Bionovo Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Aerovance Appoints Babatunde A. Otulana, M.D., as Chief Medical Officer
2. AcelRx Pharmaceuticals Hires Roman Skowronski, M.D., Ph.D. as Vice President of Clinical Development
3. Jonathan Lewis, M.D., Ph.D. Steps Down From Delcath Systems Board of Directors
4. Cerimon Pharmaceuticals Appoints James S. Shannon, M.D., to Board of Directors
5. Ethan Weiss, M.D., Joins Bionovos Scientific Advisory Board
6. Senesco Appoints Harlan W. Waksal, M.D., to Board of Directors
7. Cato T. Laurencin, M.D., Ph.D. to Join Osteotech Board of Directors
8. Orexigen(R) Therapeutics Appoints Dennis Kim, M.D., as Senior Vice President, Head of Obesity and Metabolic Disorders
9. Trusted LASIK Surgeons Welcomes Leading LASIK Eye Surgery Expert, Inventor David Huang, M.D., Los Angeles, to Its Unique Lasik Directory Service
10. Arete Therapeutics Names James Sabry, M.D., Ph.D., President and Chief Executive Officer
11. Daniel B. Dubin, M.D., Joins NanoBio Corp.s Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... -- AACC welcomed thousands of medical professionals and ... & Clinical Lab Expo in Atlanta ... revolutionary advancements in clinical testing technology and research ... diagnose patients quickly and accurately and make sure ... As of Wednesday, July 29, more than 17,500 ...
(Date:7/30/2015)... ... July 30, 2015 , ... The 2015 Market Research Report ... the current state of the global Propanol market with a focus on the Chinese ... Dow, Carboclor, Mitsui Chemicals, Oxea, ISU Chemical, Sanofi, Royal Dutch Shell, LG Chem and ...
(Date:7/30/2015)... Kan. , July 30, 2015   ... a pet therapeutics company focused on the licensing, ... companion animals, today announced that its strategic partner ... a dose confirmation study of AT-016, an adipose-derived ... for the treatment of osteoarthritis pain in dogs. ...
(Date:7/30/2015)... COPENHAGEN, Denmark , July 30, 2015 /PRNewswire/ ... a biotechnology company that applies its innovative TransCon ... announced positive top-line results from a six-month Phase ... of once-weekly TransCon Growth Hormone in 53 treatment-naïve, ... "We are extremely pleased with the ...
Breaking Biology Technology:Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4Global Propanol Market Technical Data and Manufacturing Analysis 2020 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7
... 1 SynCo Bio Partners B.V., the,expert in long ... has expanded its business into a new geographical,market, with ... biotherapeutic,for an emerging Japanese pharmaceutical company. , ... live biotherapeutic,based anticancer drug. The project will first involve ...
... , , FORT LAUDERDALE, Fla., ... a leader in integrated electronic data capture (EDC) ... fastest growing companies in the EDC marketplace, announced today that ... have joined its rapidly expanding partnership program, the CRO Preferred ...
... , , SOUTH SAN FRANCISCO, ... changing the paradigm of drug discovery and development through the ... Plunkett, Ph.D., as vice president and chief financial officer. , ... term success, and Matt,s career over the last decade has given ...
Cached Biology Technology:SynCo Bio Partners Enters the Japanese Market as it Signs its First Agreement With a Japanese Pharmaceutical Company 2OmniComm Systems Inc. Expands Its Successful CRO Preferred Program(TM) By Signing On Three New CRO Partners 2OmniComm Systems Inc. Expands Its Successful CRO Preferred Program(TM) By Signing On Three New CRO Partners 3iPierian Appoints Dr. Matthew J. Plunkett as Chief Financial Officer 2
(Date:7/13/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... on the growing mobile commerce market, announced today ... BEHAVIORAL-DIRECTED AUTHENTIATION METHOD AND SYSTEM. ... method to make payments.  With this patent, NXT-ID ... its groundbreaking voice-direct payment patent application, with behavior-directed ...
(Date:7/8/2015)... , July 8, 2015 Summary Pancreatic ... the fourth most fatal, with a mortality rate of ... prognosis of pancreatic cancer patients has highlighted a significant ... is not being met by the current market. ... of products with varying molecule types and mechanisms of ...
(Date:7/7/2015)... 7, 2015  Based on its recent analysis ... recognizes Credence ID, LLC with the 2015 Asia-Pacific ... the Year Award. Credence ID has developed a ... mission of offering enrollment and identification solutions to ... ID was formed by experts from the mobile ...
Breaking Biology News(10 mins):NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5
... Seventy-eight microbiologists have been elected to Fellowship ... of the Academy are elected annually through a ... of scientific achievement and original contributions that have ... representing all subspecialties of microbiology, including basic and ...
... Humans are sustained by a multitude of processes ... are called "ecosystem services," and include products like clean ... crops and spices. On Thursday, March 4, the ... "Ecosystem Services in a Changing World: Perspectives from Long-Term ...
... The Proceedings of the National Academy of Sciences ... PNAS papers to receive the 2009 Cozzarelli Prize, an ... by the National Academy of Sciences. Papers selected for ... articles published by PNAS in 2009 and represent ...
Cached Biology News:78 scientists elected to the American Academy of Microbiology 278 scientists elected to the American Academy of Microbiology 378 scientists elected to the American Academy of Microbiology 4NSF forum to address 'ecosystem services' in a changing world 2PNAS announces 6 2009 Cozzarelli Prize recipients 2
... signal and low background ,This solution greatly ... times higher than obtained with conventional methods. ... primary and secondary antibodies, which can suppress ... , Wide versatility ,It is applicable ...
pH-dependent fluorescence; Maximum intensity observed in basic solutions....
Mouse Anti-Human Kallikrein 2 (Hk2)...
Recognizes a full-length CLC-2 voltage-gated Cl- protein and not with other known proteins tested so far....
Biology Products: